Shares of Johnson & Johnson dropped after the company announced the sale of its stake in Kenvue.
Stock AI’s forecasts:
🔴 -6.4% short-term
🟢 +0.9% long-term
Stock AI’s (JNJ) Forecast get (+10.1% Profit)
StockAI’s analysis delivers real-world results. On 06 March 2024, $JNJ ($160.7), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $144.4 (🔴-10.1%). Selling JNJ on this signal yielded a +10.1% profit 💰💰.
JNJ-Johnson & Johnson News
🟢 Johnson & Johnson to sell remaining stake in consumer health company, positive impact expected on stock price.
🔴 Johnson & Johnson acquires Proteologix for $850 million, potential to boost stock price.
🟢 Nuvei, Walgreens Boots Alliance, and Johnson & Johnson to trade ex-dividend, could lead to short-term price decrease.
🔴 Johnson & Johnson faces lawsuit over talc powder, negative impact on stock price likely.
🟢 Johnson & Johnson announces topline results from clinical trials, positive news for stock performance.
🔴 Johnson & Johnson’s medical device subsidiary recalls patient return electrodes, negative impact expected on stock price.
Johnson & Johnson’s recent news has been a mix of positive and negative developments, which could have varying effects on the stock price. The company’s acquisition of Proteologix for $850 million is seen as a positive move that could potentially boost the stock price. However, the lawsuit over talc powder and the recall of patient return electrodes by the medical device subsidiary could have a negative impact on the stock price.
Additionally, the upcoming ex-dividend trading for Nuvei, Walgreens Boots Alliance, and Johnson & Johnson may lead to a short-term decrease in the stock price. On the other hand, the topline results from clinical trials announced by Johnson & Johnson could have a positive effect on the stock performance.
Overall, the stock price of Johnson & Johnson may experience fluctuations in the near future due to these recent developments. Investors should closely monitor the news and assess the potential impact on the stock price before making any investment decisions.
JNJ-Johnson & Johnson Analyst Ratings
In recent analyst ratings for Johnson & Johnson (NYSE: JNJ) stock, the following changes have been noted:
📈 Royal Bank of Canada reaffirmed their outperform rating on shares of Johnson & Johnson.
📉 UBS reaffirmed their buy rating on JNJ stock.
📈 Cantor Fitzgerald reiterated its overweight rating on Johnson & Johnson.
Sources:
– ETF Daily News
– ETF Daily News
– ETF Daily News
– ETF Daily News
– ETF Daily News
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
